Tags: Pfizer | Profits | Earnings | Drugs

Pfizer Beats Forecasts as Oncology Drugs Grow

Tuesday, 29 July 2014 07:56 AM

Pfizer Inc., which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.

The largest U.S. drugmaker on Tuesday said it had earned $2.91 billion, or 45 cents per share. That compared with $14.1 billion, or $1.98 per share, a year earlier, when Pfizer received more than $10 billion in proceeds from the spinoff of its animal health business into a new publicly traded company, Zoetis.

Excluding special items, Pfizer earned 58 cents per share. Analysts on average expected 57 cents, according to Thomson Reuters I/B/E/S.

Sales fell 2 percent to $12.77 billion, hurt by declines for generic medicines that Pfizer calls established products, but they exceeded Wall Street expectations of $12.46 billion.

Pfizer stuck to its prior earnings forecast of $2.20 to $2.30 per share for the full year.

Shares of Pfizer were up 1 percent at $30.41 in trading before the market opened.


© 2021 Thomson/Reuters. All rights reserved.


   
1Like our page
2Share
Companies
Pfizer Inc., which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.
Pfizer, Profits, Earnings, Drugs
159
2014-56-29
Tuesday, 29 July 2014 07:56 AM
Newsmax Media, Inc.
 
Newsmax TV Live

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved